Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 16 min read

  1. Clemente AS, Diniz BS, Nicolato R, Kapczinski FP, Soares JC, Firmo JO, Castro-Costa É. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Braz J Psychiatry 2015;37:155–61.25946396
  2. Kessing LV, Vradi E, Andersen PK. Life expectancy in bipolar disorder. Bipolar Disord 2015;17:543–8.25846854
  3. National Institute for Health and Care Excellence. Bipolar Disorder: Assessment and Management. NICE; 2014.
  4. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530–7.12044195
  5. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261–9.12622659
  6. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351–60.15994719
  7. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079–88.14609883
  8. Prescribing Observatory for Mental Health. Topic 15a Baseline Audit Report. Prescribing Valproate for Bipolar Disorder. 2016.
  9. Kupfer DJ, Frank E, Grochocinski VJ, Luther JF, Houck PR, Swartz HA, Mailinger AG. Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatr 2000;12:110–4.26975266
  10. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016;30:495–553.26979387
  11. Willner P, Lappas S, Cheeta S, Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl) 1994;115:454–62.7871089
  12. Kitagawa K, Kitamura Y, Miyazaki T, Miyaoka J, Kawasaki H, Asanuma M, et al. Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol 2009;380:59–66.19274453
  13. Chiu WH, Depboylu C, Hermanns G, Maurer L, Windolph A, Oertel WH, et al. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson’s disease. Neuropharmacology 2015;95:367–76.25839898
  14. Breuer ME, Groenink L, Oosting RS, Buerger E, Korte M, Ferger B, Olivier B. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Eur J Pharmacol 2009;616:134–40.19549514
  15. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001;25:836–44.11750177
  16. Serafini G, Hayley S, Pompili M, Dwivedi Y, Brahmachari G, Girardi P, Amore M. Hippocampal neurogenesis, neurotrophic factors and depression: possible therapeutic targets? CNS Neurol Disord Drug Targets 2014;13:1708–21.25470403
  17. Shen T, Ye R, Zhang B. Efficacy and safety of pramipexole extended-release in Parkinson’s disease: a review based on meta-analysis of randomized controlled trials. Eur J Neurol 2017;24:835–43.28480621
  18. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009;31:89–98.19243709
  19. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573–80.20452823
  20. Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, Howes OD. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 2017;22:666–79.28289283
  21. Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000;12:137–40.10984002
  22. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001;34:137–41.11518474
  23. Lattanzi L, Dell’Osso L, Cassano P, Pini S, Rucci P, Houck PR, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002;4:307–14.12479663
  24. El-Mallakh RS, Penagaluri P, Kantamneni A, Gao Y, Roberts RJ. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q 2010;81:207–13.20425143
  25. Hori H, Kunugi H. The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial. ScientificWorldJournal 2012;2012:372474.22919308
  26. Dell’osso B, Timtim S, Hooshmand F, Miller S, Wang PW, Hill SJ, et al. Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder. J Affect Disord 2013;150:130–5.23261131
  27. Fawcett J, Rush AJ, Vukelich J, Diaz SH, Dunklee L, Romo P, et al. Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression. Am J Psychiatry 2016;173:107–11.26844792
  28. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564–6.14992985
  29. Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54–60.15219473
  30. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006;10:515–31.16848689
  31. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28:1065–78.16982285
  32. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995;290:29–36.7664822
  33. Deutschlander A, la Fougere C, Boetzel K, Albert NL, Gildehaus FJ, Bartenstein P, et al. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson’s disease patients. Neuroimage Clin 2016;12:41–6.27408789
  34. Landwehrmeyer B, Mengod G, Palacios JM. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci 1993;5:145–53.8261096
  35. Burns LH, Robbins TW, Everitt BJ. Differential effects of excitotoxic lesions of the basolateral amygdala, ventral subiculum and medial prefrontal cortex on responding with conditioned reinforcement and locomotor activity potentiated by intra-accumbens infusions of D-amphetamine. Behav Brain Res 1993;55:167–83.8357526
  36. Robbins TW, Everitt BJ. Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 1996;6:228–36.8725965
  37. Caravaggio F, Fervaha G, Browne CJ, Gerretsen P, Remington G, Graff-Guerrero A. Reward motivation in humans and its relationship to dopamine D(2/3) receptor availability: a pilot study with dual [(11)C]-raclopride and [(11)C]-(+)-PHNO imaging. J Psychopharmacol 2018;32:357–66.29442593
  38. Collo G, Cavalleri L, Bono F, Mora C, Fedele S, Invernizzi RW, et al. Ropinirole and pramipexole promote structural plasticity in human iPSC-derived dopaminergic neurons via BDNF and mTOR signaling. Neural Plast 2018;2018:4196961.29531524
  39. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008;33:88–109.17851537
  40. Rotheneichner P, Lange S, O’Sullivan A, Marschallinger J, Zaunmair P, Geretsegger C, et al. Hippocampal neurogenesis and antidepressive therapy: shocking relations. Neural Plast 2014;2014:723915.24967107
  41. Levy MJF, Boulle F, Steinbusch HW, van den Hove DLA, Kenis G, Lanfumey L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology 2018;235:2195–220.29961124
  42. Kandola A, Ashdown-Franks G, Hendrikse J, Sabiston CM, Stubbs B. Physical activity and depression: towards understanding the antidepressant mechanisms of physical activity. Neurosci Biobehav Rev 2019;107:525–39.31586447
  43. Wang J, Jia Y, Li G, Wang B, Zhou T, Zhu L, et al. The dopamine receptor D3 regulates lipopolysaccharide-induced depressive-like behavior in mice. Int J Neuropsychopharmacol 2018;21:448–60.29390063
  44. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun 2020;87:901–9.32113908
  45. Misiak B, Bartoli F, Carra G, Malecka M, Samochowiec J, Jarosz K, et al. Chemokine alterations in bipolar disorder: a systematic review and meta-analysis. Brain Behav Immun 2020;88:870–7.32278851
  46. Michels L, Scherpiet S, Stampfli P, Herwig U, Bruhl AB. Baseline perfusion alterations due to acute application of quetiapine and pramipexole in healthy adults. Int J Neuropsychopharmacol 2016;19:pyw067.27466220
  47. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543–52.17485606
  48. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith SH. Paying the Price: The Cost of Mental Health Care in England to 2026. London: The King's Fund; 2008.
  49. Young AH, Rigney U, Shaw S, Emmas C, Thompson JM. Annual cost of managing bipolar disorder to the UK healthcare system. J Affect Disord 2011;133:450–6.21737141
  50. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, Calabrese JR. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171:169–77.24170221
  51. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, Sachs G. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171:160–8.24170180
  52. Bernstein IH, Rush AJ, Stegman D, Macleod L, Witte B, Trivedi MH. A comparison of the QIDS-C16, QIDS-SR16, and the MADRS in an adult outpatient clinical sample. CNS Spectr 2010;15:458–68.20625366
  53. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905–17.17074942
  54. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011;168:689–701.21536692
  55. Martinez JM, Katon W, Greist JH, Kroenke K, Thase ME, Meyers AL, et al. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol 2012;27:17–26.22027844
  56. Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM. ABCB1 genetic effects on antidepressant outcomes: a report from the ISPOT-D trial. Am J Psychiatry 2015;172:751–9.25815420
  57. Azim L, Hindmarch P, Browne G, Chadwick T, Clare E, Courtney P, et al. Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study). BMC Psychiatry 2021;21:334.34225686
  58. BALANCE investigators and collaborators; Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375:385–95.20092882
  59. Geddes JR, Gardiner A, Rendell J, Voysey M, Tunbridge E, Hinds C, et al.; CEQUEL Investigators and Collaborators. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 2016;3:31–9.26687300
  60. Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for impulsive-compulsive disorders in Parkinson’s Disease-Rating Scale. Mov Disord 2012;27:242–7.22134954
  61. McIntyre RS, Lipsitz O, Lui LMW, Rodrigues NB, Gill H, Nasri F, et al. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. J Affect Disord 2021;294:592–6.34332360
  62. Jha MK, South C, Trivedi J, Minhajuddin A, Rush AJ, Trivedi MH. Prediction of acute-phase treatment outcomes by adding a single-item measure of activity impairment to symptom measurement: development and validation of an interactive calculator from the STAR*D and CO-MED trials. Int J Neuropsychopharmacol 2019;22:339–48.30958879
  63. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22–33;quiz 34.
  64. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th edn. Arlington, VA: American Psychiatric Association; 2013.
  65. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12.14987333
  66. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–7.16717171
  67. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith–Hamilton Pleasure Scale. Br J Psychiatry 1995;167:99–103.7551619
  68. Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry 2002;180:461–4.11983645
  69. Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman Self-Rating Mania Scale. Biol Psychiatry 1997;42:948–55.9359982
  70. Moraga-Amaro R, Gonzalez H, Pacheco R, Stehberg J. Dopamine receptor D3 deficiency results in chronic depression and anxiety. Behav Brain Res 2014;274:186–93.25110304
  71. Jordan CJ, Humburg B, Rice M, Bi GH, You ZB, Shaik AB, et al. The highly selective dopamine D(3)R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents. Neuropharmacology 2019;158:107597.30974107
  72. Groman SM, Hillmer AT, Liu H, Fowles K, Holden D, Morris ED, et al. Midbrain D(3) receptor availability predicts escalation in cocaine self-administration. Biol Psychiatry 2020;88:767–76.32312578
  73. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429–35.728692
  74. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9.444788
  75. EU Parliament. EU Directive on Good Clinical Practise; 2005.
  76. Jay R. Data Protection Act 1998. Hamilton A, editor. London: Sweet & Maxwell; 1999.
  77. Great Britain. Data Protection Act 2018. Chapter 12. London: The Stationery Office; 2018.
  78. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.21479777
  79. Keeley T, Al-Janabi H, Lorgelly P, Coast J. A qualitative assessment of the content validity of the ICECAP-A and EQ-5D-5L and their appropriateness for use in health research. PLOS ONE 2013;8:e85287.24367708
  80. Mitchell PM, Al-Janabi H, Byford S, Kuyken W, Richardson J, Iezzi A, Coast J. Assessing the validity of the ICECAP-A capability measure for adults with depression. BMC Psychiatry 2017;17:46.28148234
  81. Vergunst F, Jenkinson C, Burns T, Anand P, Gray A, Rugkasa J, Simon J. Psychometric validation of a multi-dimensional capability instrument for outcome measurement in mental health research (OxCAP-MH). Health Qual Life Outcomes 2017;15:250.29282075
  82. Simon J, Anand P, Gray A, Rugkasa J, Yeeles K, Burns T. Operationalising the capability approach for outcome measurement in mental health research. Soc Sci Med 2013;98:187–96.24331898
  83. Hughes-Morley A, Young B, Waheed W, Small N, Bower P. Factors affecting recruitment into depression trials: systematic review, meta-synthesis and conceptual framework. J Affect Disord 2015;172:274–90.25451427
  84. McAllister-Williams RH, Goudie N, Azim L, Bartle V, Berger M, Butcher C, et al. A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study). J Psychopharmacol 2025;39(2):106–20. 10.1177/0269881124130962239829389
  85. Barrios C, Chaudhry TA, Goodnick PJ. Rapid cycling bipolar disorder. Expert Opin Pharmacother 2001;2:1963–73.11825328
  86. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007;68:1230–6.17854248
  87. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. URL: https://bnf.nice.org.uk/drugs/pramipexole/#side-effects (accessed January 2024).
  88. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care 2022;38:e13. 10.1017/S026646232100173235007499
  89. Drummond MF. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University Press; 2005.
  90. TrueColours on-line self-management system, hosted by Oxford Health NHS Foundation Trust, Oxford, UK.
  91. Simon J, Mayer S, Laszewska A, Rugkasa J, Yeeles K, Burns T, Gray A. Cost and quality-of-life impacts of community treatment orders (CTOs) for patients with psychosis: economic evaluation of the OCTET trial. Soc Psychiatry Psychiatr Epidemiol 2021;56:85–95.32719905
  92. National Institute for Health and Care Excellence. NICE Health Technology Evaluations: The Manual. 2022. URL: www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation (accessed January 2024).
  93. Kasuya A. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.10109801
  94. Helter TM, Coast J, Laszewska A, Stamm T, Simon J. Capability instruments in economic evaluations of health-related interventions: a comparative review of the literature. Qual Life Res 2020;29:1433–64.31875309
  95. Laszewska A, Helter TM, Nagel A, Peric N, Simon J. Patient-reported outcome measures suitable for quality of life/well-being assessment in multisectoral, multinational and multiperson mental health economic evaluations. Evid Based Ment Health 2022;25:85–92.34949634
  96. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res 2012;21:167–76.21598064
  97. Flynn TN, Huynh E, Peters TJ, Al-Janabi H, Clemens S, Moody A, Coast J. Scoring the ICECAP-A capability instrument. Estimation of a UK general population tariff. Health Econ 2015;24:258–69.24254584
  98. Simon J, Mayer S. HEQ (Health Economics Questionnaire). Version 08-09-2016, Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria. URL: 10.5281/zenodo.4559790; 2016.
  99. Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, et al. The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial. Trials 2017;18:558.29169399
  100. Chisolm D, Knapp M, Knudsen H, et al. Client socio-demographic and service receipt inventory - European version: development of an instrument for international research. Br J Psychiatry, 2000, 177, s28–s33. 10.1192/bjp.177.39.s28
  101. Hakkaart-van Roijen L, van Straten A, Donker M, Tiemens BManual Trimbos/iMTA questionnaire for Costs associated with Psychiatric illness (TiC-P),Version September 2010. Rotterdam: Institute for Medical Technology Assessment; 2002.
  102. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006;77:51–63.16139925
  103. NICE. Managing Long-Term Sickness Absence and Incapacity for Work. NICE; 2019.
  104. Jones KC, Burns A. Unit Costs of Health and Social Care 2021. PSSRU, University of Kent; 2021.
  105. Little RJA, Rubin DB, editors. Statistical Analysis with Missing Data: Little/Statistical Analysis with Missing Data; 2002.
  106. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–99.21225900
  107. Efron B, Tibshirani R. An Introduction to the Bootstrap (1st ed.). New York: Chapman and Hall/CRC; 1994.
  108. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106–8.16055820
  109. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18:S68–80.9566468
  110. McAllister-Williams RH, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, et al. Reconceptualising treatment-resistant depression as difficult-to-treat depression. Lancet Psychiatry 2021;8:14–5.33341160
  111. Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, et al.; EUROPAR and the IPMDS Non-Motor-PD-Study Group. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 2016;23:1255–61.27170229
  112. Chan CC, Alter S, Hazlett EA, Shafritz KM, Yehuda R, Goodman M, et al. Neural correlates of impulsivity in bipolar disorder: a systematic review and clinical implications. Neurosci Biobehav Rev 2023;147:105109.36813146
  113. Guerrero-Bautista R, Do Couto BR, Hidalgo JM, Cárceles-Moreno FJ, Molina G, Laorden ML, et al. Modulation of stress- and cocaine prime-induced reinstatement of conditioned place preference after memory extinction through dopamine D3 receptor. Prog Neuropsychopharmacol Biol Psychiatry 2019;92:308–20.30707990
  114. Leggio GM, Di Marco R, Gulisano W, D’Ascenzo M, Torrisi SA, Geraci F, et al. Dopaminergic-GABAergic interplay and alcohol binge drinking. Pharmacol Res 2019;141:384–91.30648615
  115. Whitton AE, Reinen JM, Slifstein M, Ang YS, McGrath PJ, Iosifescu DV, et al. Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. Brain 2020;143:701–10.32040562
  116. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573–83.12946886
  117. Carmody TJ, Rush AJ, Bernstein IH, Brannan S, Husain MM, Trivedi MH. Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS. J Affect Disord 2006;95:115–8.16707162
  118. De Wit LE, Wilting I, Souverein PC, van der Pol P, Egberts TCG. Impulse control disorders associated with dopaminergic drugs: a disproportionality analysis using vigibase. Eur Neuropsychopharmacol 2022;58:30–8.35189453
  119. Pompili M, Verzura C, Trovini G, Buscajoni A, Falcone G, Naim S, et al. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders. Expert Opin Drug Saf 2018;17:197–205.28902525
  120. Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. Lurasidone in the long‐term treatment of patients with bipolar disorder: a 24‐week open‐label extension study. Depress Anxiety 2016;33:424–34.26918425
  121. Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Di Florio A, Dietch D, et al. Treatment-resistant and multi-therapy resistant criteria for bipolar depression: consensus definition – CORRIGENDUM. Br J Psychiatry 2019;214:309.30816078
  122. Byrom B, Mundt JC. The value of computer-administered self-report data in central nervous system clinical trials. Curr Opin Drug Discov Devel 2005;8:374–83.
  123. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347–54.16139580
  124. Hughes T, Cardno A, West R, Marino-Francis F, Featherstone I, Rolling K, et al. Unrecognised bipolar disorder among UK primary care patients prescribed antidepressants: an observational study. Br J Gen Pract 2016;66:e71–7.26740604
  125. Wilson P, Mathie E, Keenan J, McNeilly E, Goodman C, Howe A, et al.; Health Services and Delivery Research. ReseArch with Patient and Public invOlvement: a RealisT evaluation – the RAPPORT study. Southampton (UK): NIHR Journals Library Copyright © Queen’s Printer and Controller of HMSO; 2015.
← ConclusionAdditional information →

Attribution. Hamish McAllister-Williams; Nicola Goudie; Lumbini Azim; Victoria Bartle; Michael Berger; Chrissie Butcher et al. (2025). Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial. National Institute for Health and Care Research. Copyright © 2025 McAllister-Williams et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK615187. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support